The current status of malaria vaccines

José A. Stoute, W. Ripley Ballou

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

A vaccine against Plasmodium falciparum malaria is needed now more than ever due the resurgence of the parasite and the increase in drug resistance. However, success in developing an effective malaria vaccine has been elusive. Among pre-erythrocytic antigens, the major antigen coating the surface of the sporozoite, the circumsporozoite protein (CS), has been, and continues to be, the major target for vaccine development. Despite initial limited success with CS-based vaccines, the use of new adjuvant formulations has led to the development of a promising candidate (the RTS,S vaccine) which has shown significant efficacy in a preliminary trial. In addition to CS, many other malaria antigens have been identified that play an important role in the parasite life cycle which are being considered for, or are currently undergoing, clinical trials. Among the blood stage antigens, the merozoite surface protein 1 (MSP-1) is the most promising vaccine candidate. New approaches to immunisation against malaria being considered include the use of multistage, multicomponent vaccines in attenuated viral vectors (NYVAC- Pf7), or in a combination DNA vaccine. While there is reason to be optimistic about the prospects for an effective vaccine, many challenges lie ahead that still have to be overcome. Among these are the antigenic polymorphism exhibited by wild parasite strains and the genetic restriction of immune responses.

Original languageEnglish (US)
Pages (from-to)123-136
Number of pages14
JournalBioDrugs
Volume10
Issue number2
DOIs
StatePublished - Jan 1 1998

Fingerprint

Malaria Vaccines
Vaccines
Parasites
Antigens
Malaria
Merozoite Surface Protein 1
Combined Vaccines
Sporozoites
Attenuated Vaccines
Proteins
DNA Vaccines
Falciparum Malaria
Surface Antigens
Life Cycle Stages
Drug Resistance
Immunization
Clinical Trials

All Science Journal Classification (ASJC) codes

  • Biotechnology
  • Pharmacology
  • Pharmacology (medical)

Cite this

Stoute, José A. ; Ballou, W. Ripley. / The current status of malaria vaccines. In: BioDrugs. 1998 ; Vol. 10, No. 2. pp. 123-136.
@article{df1395e64dec4747a183956a0d8a2c0f,
title = "The current status of malaria vaccines",
abstract = "A vaccine against Plasmodium falciparum malaria is needed now more than ever due the resurgence of the parasite and the increase in drug resistance. However, success in developing an effective malaria vaccine has been elusive. Among pre-erythrocytic antigens, the major antigen coating the surface of the sporozoite, the circumsporozoite protein (CS), has been, and continues to be, the major target for vaccine development. Despite initial limited success with CS-based vaccines, the use of new adjuvant formulations has led to the development of a promising candidate (the RTS,S vaccine) which has shown significant efficacy in a preliminary trial. In addition to CS, many other malaria antigens have been identified that play an important role in the parasite life cycle which are being considered for, or are currently undergoing, clinical trials. Among the blood stage antigens, the merozoite surface protein 1 (MSP-1) is the most promising vaccine candidate. New approaches to immunisation against malaria being considered include the use of multistage, multicomponent vaccines in attenuated viral vectors (NYVAC- Pf7), or in a combination DNA vaccine. While there is reason to be optimistic about the prospects for an effective vaccine, many challenges lie ahead that still have to be overcome. Among these are the antigenic polymorphism exhibited by wild parasite strains and the genetic restriction of immune responses.",
author = "Stoute, {Jos{\'e} A.} and Ballou, {W. Ripley}",
year = "1998",
month = "1",
day = "1",
doi = "10.2165/00063030-199810020-00004",
language = "English (US)",
volume = "10",
pages = "123--136",
journal = "BioDrugs",
issn = "1173-8804",
publisher = "Adis International Ltd",
number = "2",

}

The current status of malaria vaccines. / Stoute, José A.; Ballou, W. Ripley.

In: BioDrugs, Vol. 10, No. 2, 01.01.1998, p. 123-136.

Research output: Contribution to journalReview article

TY - JOUR

T1 - The current status of malaria vaccines

AU - Stoute, José A.

AU - Ballou, W. Ripley

PY - 1998/1/1

Y1 - 1998/1/1

N2 - A vaccine against Plasmodium falciparum malaria is needed now more than ever due the resurgence of the parasite and the increase in drug resistance. However, success in developing an effective malaria vaccine has been elusive. Among pre-erythrocytic antigens, the major antigen coating the surface of the sporozoite, the circumsporozoite protein (CS), has been, and continues to be, the major target for vaccine development. Despite initial limited success with CS-based vaccines, the use of new adjuvant formulations has led to the development of a promising candidate (the RTS,S vaccine) which has shown significant efficacy in a preliminary trial. In addition to CS, many other malaria antigens have been identified that play an important role in the parasite life cycle which are being considered for, or are currently undergoing, clinical trials. Among the blood stage antigens, the merozoite surface protein 1 (MSP-1) is the most promising vaccine candidate. New approaches to immunisation against malaria being considered include the use of multistage, multicomponent vaccines in attenuated viral vectors (NYVAC- Pf7), or in a combination DNA vaccine. While there is reason to be optimistic about the prospects for an effective vaccine, many challenges lie ahead that still have to be overcome. Among these are the antigenic polymorphism exhibited by wild parasite strains and the genetic restriction of immune responses.

AB - A vaccine against Plasmodium falciparum malaria is needed now more than ever due the resurgence of the parasite and the increase in drug resistance. However, success in developing an effective malaria vaccine has been elusive. Among pre-erythrocytic antigens, the major antigen coating the surface of the sporozoite, the circumsporozoite protein (CS), has been, and continues to be, the major target for vaccine development. Despite initial limited success with CS-based vaccines, the use of new adjuvant formulations has led to the development of a promising candidate (the RTS,S vaccine) which has shown significant efficacy in a preliminary trial. In addition to CS, many other malaria antigens have been identified that play an important role in the parasite life cycle which are being considered for, or are currently undergoing, clinical trials. Among the blood stage antigens, the merozoite surface protein 1 (MSP-1) is the most promising vaccine candidate. New approaches to immunisation against malaria being considered include the use of multistage, multicomponent vaccines in attenuated viral vectors (NYVAC- Pf7), or in a combination DNA vaccine. While there is reason to be optimistic about the prospects for an effective vaccine, many challenges lie ahead that still have to be overcome. Among these are the antigenic polymorphism exhibited by wild parasite strains and the genetic restriction of immune responses.

UR - http://www.scopus.com/inward/record.url?scp=0031694328&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031694328&partnerID=8YFLogxK

U2 - 10.2165/00063030-199810020-00004

DO - 10.2165/00063030-199810020-00004

M3 - Review article

C2 - 18020590

AN - SCOPUS:0031694328

VL - 10

SP - 123

EP - 136

JO - BioDrugs

JF - BioDrugs

SN - 1173-8804

IS - 2

ER -